Sapience Pharma Receives NMPA Registration Certificate for Citrate Sildenafil Orally Disintegrating Tablets on May 25

GateNews
Sapience Pharma announced on May 25 that it received a drug registration certificate for Citrate Sildenafil Orally Disintegrating Tablets from China's National Medical Products Administration (NMPA). The drug is classified as a chemical drug category 4 and is indicated for treating erectile dysfunction. As of the announcement date, the company had accumulated approximately 9.915 million yuan in research and development investments for this drug. The new product is expected to enrich the company's product portfolio and optimize its product structure.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments